NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo”) announced today that the United States Patent and Trademark Office has declared a patent interference between an allowed patent application of its subsidiary, Enzo Life Sciences, Inc., and a patent held by California Institute of Technology (“Cal Tech”) and licensed exclusively to Applied Biosystems, Inc., a division of Applera Corporation (NYSE:ABI). The technology involves gel sequencing, which is the primary technique for sequencing DNA.
